Exosome: A Novel and Safer Therapeutic Refinement of Mesenchymal Stem Cell

Authors

  • Ronne Wee Yeh Yeo Institute of Medical Biology, Agency for Science, Technology and Research, Singapore
  • Ruenn Chai Lai Institute of Medical Biology, Agency for Science, Technology and Research, Singapore
  • Kok Hian Tan Department of Maternal Fetal Medicine, KK Women's and Children's Hospital, Singapore
  • Sai Kiang Lim Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

DOI:

https://doi.org/10.33393/jcb.2013.2038

Keywords:

Exosomes, Mesenchymal Stem Cell, Myocardial Ischemia / Reperfusion Injury, Purification

Abstract

Mesenchymal stem cell (MSC) has just been approved as the first “off-the-shelf” stem cell pharmaceutical drug with an anticipation of more approvals following completion of numerous rigorous clinical trials. Despite this progress, the rationale for MSC therapeutic efficacy remains tenuous and is increasingly rationalized on a secretion rather than differentiation mechanism. Recent studies identifying exosome as the secreted agent mediating MSC therapeutic efficacy could potentially reduce a cell-based drug to a safer biologic-based alternative. Here we review the development of MSC exosome as a potential first-in-class therapeutic, and the unique challenges in the manufacture and regulatory oversight of this new class of therapeutics.

Downloads

Download data is not yet available.

Downloads

Published

2013-01-01

How to Cite

Yeo, R. W. Y., Lai, R. C., Tan, K. H., & Lim, S. K. (2013). Exosome: A Novel and Safer Therapeutic Refinement of Mesenchymal Stem Cell. Journal of Circulating Biomarkers, 1(1). https://doi.org/10.33393/jcb.2013.2038

Issue

Section

Original research article

Metrics